Price Alert

Chugai Pharmaceutical Co.... (CHGCY)

OTC: CHGCY · Real-Time Price · USD

23.80

0.64 (2.76%)

At close: Oct 03, 2025, 3:59 PM

23.89

0.40%

After-hours: Oct 03, 2025, 04:00 PM EDT

Chugai Pharmaceutical Income Statement

Financials in JPY. Fiscal year is January - December.

Fiscal Year	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021
Revenue	1,196.2B	1,222.1B	1,170.6B	1,142.3B	1,084.6B	1,036.1B	1,111.4B	1,276B	1,243.4B	1,211.6B	1,259.9B	1,143.7B	1,205.7B	1,191.5B	999.76B	887.92B	809.05B	776.34B
Cost of Revenue	354.41B	354.28B	339.41B	337.17B	331.21B	334.93B	413.31B	534.15B	525B	513.16B	476.25B	373.9B	409B	397.23B	338.15B	299.86B	265.02B	267.53B
Gross Profit	841.8B	867.84B	831.2B	805.18B	753.36B	701.15B	698.06B	741.89B	718.44B	698.48B	783.7B	769.82B	796.7B	794.26B	661.61B	588.06B	544.03B	508.81B
Operating Income	545.8B	576.44B	541.34B	534.62B	480.9B	435.19B	431.94B	467.07B	457.27B	444.6B	533.31B	522.9B	548.17B	544.94B	421.9B	356.75B	321.28B	292.79B
Interest Income	n/a	480M	495M	2.38B	2.38B	3.29B	4.65B	3.29B	3.3B	2.7B	2.94B	2.42B	2.4B	1.61B	n/a	n/a	n/a	n/a
Pretax Income	556.17B	578.97B	543.03B	540.22B	488.86B	444.05B	443.82B	470.35B	457.9B	444.62B	531.17B	520.39B	545.05B	541.35B	419.38B	354B	319.88B	291.21B
Net Income	395.44B	410.15B	387.32B	386.96B	355.04B	326.37B	325.47B	336.75B	326.97B	316.15B	374.43B	370.79B	389.01B	387.36B	303B	256.46B	230.58B	210.61B
Selling & General & Admin	111.84B	110.75B	108.69B	101.83B	101.6B	107.55B	107.38B	112.7B	107.75B	96.52B	100.76B	104.72B	106.84B	107.89B	102.42B	98.99B	96.49B	94.55B
Research & Development	179.2B	176.47B	176.81B	170.98B	171.63B	173.27B	174.87B	178.24B	169.38B	158.63B	149.63B	142.2B	141.69B	141.44B	137.3B	132.32B	126.27B	121.48B
Other Expenses	4.96B	4.18B	4.36B	-2.25B	-603M	n/a	-1.27B	-1B	-1B	-1B	267M	259M	259M	255M	255M	-361M	-624M	-968M
Operating Expenses	296B	291.4B	289.86B	270.57B	272.47B	265.96B	266.13B	274.82B	261.17B	253.88B	250.39B	246.92B	248.53B	249.33B	239.72B	231.32B	222.76B	216.02B
Interest Expense	n/a	n/a	n/a	9M	16M	25M	27M	34M	42M	48M	60M	1B	998M	995M	993M	56M	63M	62M
Selling & Marketing Expenses	n/a	27.32B	49.9B	80.66B	108.2B	114.15B	112.58B	104.86B	96.14B	81.38B	77.15B	78.46B	78.09B	77.51B	76.59B	75.05B	73.55B	72.69B
Cost & Expenses	650.41B	645.68B	629.27B	607.74B	603.67B	600.89B	679.43B	808.98B	786.16B	767.03B	726.64B	620.82B	657.53B	646.56B	577.86B	531.17B	487.78B	483.55B
Income Tax Expense	160.73B	168.82B	155.72B	153.25B	133.82B	117.68B	118.35B	133.6B	130.93B	128.47B	156.74B	149.6B	156.04B	153.99B	116.39B	97.53B	89.3B	80.6B
Shares Outstanding (Basic)	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B
Shares Outstanding (Diluted)	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B	3.29B
EPS (Basic)	120.15	124.61	117.68	117.58	107.89	99.19	98.92	102.35	99.38	96.10	113.83	112.73	118.28	117.79	92.14	78.01	70.15	64.08
EPS (Diluted)	120.14	124.60	117.67	117.57	107.88	99.17	98.90	102.33	99.36	96.08	113.79	112.69	118.22	117.72	92.09	77.97	70.11	64.04
EBITDA	588.81B	610.04B	572.87B	548.51B	495.19B	450.87B	450.66B	470.38B	457.95B	444.67B	531.23B	520.45B	545.1B	541.4B	419.43B	354.05B	319.94B	291.27B
EBIT	557.15B	578.78B	542B	540.18B	487.25B	442.93B	442.73B	470.38B	457.95B	444.67B	531.23B	520.45B	545.1B	541.4B	419.43B	354.05B	319.94B	291.27B
Depreciation & Amortization	31.66B	31.66B	31.66B	9.13B	9.04B	9.04B	9.13B	1.8B	2B	1.9B	1.7B	3.2B	3.1B	4B	4B	9.49B	9.43B	8.58B